Antibody and protein engineering at Festival of Biologics 2026

Oct 13–15, 2026 Basel, Switzerland ~3k attendees Website

67 organizations at Festival of Biologics 2026 present work in antibody & protein engineering: 42 suppliers and service providers, 14 drug developers and 11 academic, government and non-profit bodies. Between them they bring 110 presentations to the program. Most represented: Novartis (29 on the program), Sanofi (9 on the program), AstraZeneca (6 on the program). 58 of them have their own page in this guide. As of Sep 26, 2026.

All 378 organizations at Festival of Biologics 2026 →

Showing 1–3 of 67 organizations

Organization	Festival of Biologics 2026 Attendance
Novartis Basel, Switzerland
novartis.com/about/manufacturing/contract-manufacturing Large pharmaGold sponsor Global pharmaceutical company whose contract manufacturing arm offers CDMO services for biologics, small molecules, cell and gene therapy, and fill-finish.	Booth Exhibiting at Booth 185 Keynote Tue Oct 13 09:10 Biotechnology, the Renaissance How advances in biology, AI and new treatment types are converging to change what medicine can do for patients. Chair Tue Oct 13 11:25 Chair's Remarks Clinical Trials Keynotes Chair Tue Oct 13 11:25 Chair's Remarks Antibody Keynotes Chair Tue Oct 13 11:25 Chair's Remarks Immunotherapy Keynotes Talk Tue Oct 13 11:30 Cell Line Development: Powering the Biotherapeutics Pipeline, Accelerating Patient Impact Bioprocessing Keynotes Panel Tue Oct 13 12:20 PANEL DISCUSSION: The Next Frontier: Delivering Next-Gen Science for Patients with High Unmet Need Immunotherapy Keynotes · with Memorial Sloan Kettering Cancer Center, STAb Therapeutics, Transgene +1 more Chair Tue Oct 13 14:05 Chair's Remarks Clinical Development & Operations Talk Tue Oct 13 14:50 Intensified Upstream Processing: Fed‑Batch and Perfusion Options for Robust Scale-Up Ways to get more protein from cell cultures by feeding them steadily or continuously, and how to scale that up reliably. Talk Tue Oct 13 15:10 AI for Immunogenicity Prediction of Biologics AI & Computational Approaches Panel Tue Oct 13 15:10 Panel Discussion: From Research to GMP: Making MSC Manufacturing Reproducible at Scale How to grow mesenchymal stromal cells, a kind of stem cell, the same way batch after batch as production scales up. with CSEM, HINA Bioventures, Corning Life Sciences Talk Tue Oct 13 15:30 Antibody x Conjugates: ADCs, AOCs and AxCs mAbs Chair Tue Oct 13 16:45 Chair's Remarks Protein Engineering Panel Tue Oct 13 17:30 Panel Discussion: Next Generation Antibody Formats Where antibody drug design is heading, from two-target antibodies and antibody-drug conjugates to AI's role in engineering them. with UCB, FairJourney Biologics, JJP Biologics Talk Tue Oct 13 17:30 What AI can do – or not – in Patient Engagement What AI can and cannot do when drug developers involve patients in research, and how to measure whether that involvement helps. Chair Wed Oct 14 11:25 Chair's Remarks Gene Therapy Chair Wed Oct 14 11:25 Chair's Remarks Downstream Processing Talk Wed Oct 14 11:30 The Good, the Bad and the Aggregated (Solving Protein Purification Mysteries)? Downstream Processing Talk Wed Oct 14 12:10 Introducing PAT into control strategies CMC & Developability Talk Wed Oct 14 12:30 Bovine AAV – a promising vector for pulmonary gene therapy Early results from using a cattle adeno-associated virus to deliver gene therapy to the lungs, including how immune systems recognise it. Talk Wed Oct 14 12:30 Title TBA AI & Computational Approaches Chair Wed Oct 14 14:05 Chair's Remarks AI & Computational Approaches Talk Wed Oct 14 14:30 Commercial Considerations for CAR-T Therapy: Lessons Learned from Recent Blockbusters What makes CAR-T cancer therapies hard to sell worldwide, from complex manufacturing and shipping to getting treatment centres and payers ready. Talk Wed Oct 14 15:30 When the Target Moves: Building Robust DSP Through Science, Monitoring, and Learning Why purification steps that once worked can start failing when the material feeding them changes, and how monitoring catches that early. Chair Wed Oct 14 16:45 Chair's Remarks Disease Areas: Neurodegenerative & CNS Chair Wed Oct 14 16:45 Chair's Remarks Regulated Bioanalysis Talk Wed Oct 14 16:50 The pivotal role of regulated bioanalysis in biotherapeutics development and approval Regulated Bioanalysis Talk Wed Oct 14 17:30 Protein Quality as a Critical Factor in Target Interference Assessment for Bioanalytical Assays How the quality of a lab-made protein can distort tests that check whether patients make antibodies against a biologic drug. Talk Wed Oct 14 17:50 An Oligonucleotide Program in Late-Stage Clinical Trials Lessons from keeping an anti-drug antibody test working for a cholesterol-lowering siRNA drug through late trials and a handover to a partner lab. Keynote Thu Oct 15 09:05 From Strategy to Delivery: Aligning Bioanalytical Innovation and Execution Across Clinical Phases How to decide what to measure, when and why, as biologic drugs move from early studies into late-stage clinical trials. Talk Thu Oct 15 09:40 Scaling the Future of Cell & Gene Therapies: From Scientific Innovation to Sustainable Platforms Manufacturing Chair Thu Oct 15 11:15 Chair's Remarks Fill/Finish Chair Thu Oct 15 11:15 Chair's Remarks Immunogenicity
Sanofi Paris, France
	Talk Tue Oct 13 14:10 Drug product development for biologics Formulation Talk Tue Oct 13 14:10 The New Breath: Clinical data from Lunsekimig, a bispecific anti-thymic stromal lymphopoetin (TSLP)/anti-interleukin 13 (IL-13) NANOBODY® molecule in asthma Protein Engineering Talk Tue Oct 13 15:10 Antibody Secreting Cells Repertoire For Drug Discovery, Potential & Reality mAbs Talk Tue Oct 13 17:10 VHH Antibody Discovery Pipeline Combining Cell-Free Expression in Picoliter Droplets and Bead-Based Digital Droplet PC mAbs Talk Tue Oct 13 17:50 AI systems for wearable sensors in digital clinical trials AI & Computational Approaches Talk Wed Oct 14 11:30 De Novo Design Via Computational Platforms AI & Computational Approaches Talk Wed Oct 14 14:50 Breaking the Nanobody® half-life ceiling: pH-dependent Nanobody® molecules targeting a distinct FcRn epitope enable superior pharmacokinetics and broad therapeutic applications A small antibody fragment that binds a new site on the receptor controlling protein recycling, letting the drug last longer in the body. Talk Thu Oct 15 12:00 Scalable production of 3D in vitro models using hydrogel microbead technology Analytics & Screening Talk Thu Oct 15 12:40 Antibody Sequencing And Screening Technologies Analytics & Screening
AstraZeneca Cambridge, United Kingdom
	Talk Tue Oct 13 16:50 Optimizing recombinant protein expression workflows by leveraging automation and predictive models Ways to speed up making proteins in the lab by combining automated workflows with models that predict the best genetic code choices. Talk Tue Oct 13 17:50 Advancing Antibody Discovery Through Integrated single B-Cell Technologies How to find therapeutic antibodies by profiling individual immune B cells, and how computer predictions are combined with the laboratory work. Talk Wed Oct 14 12:30 High throughput analysis supporting cell line development CMC & Developability Chair Wed Oct 14 16:45 Chair's Remarks CMC & Developability Talk Wed Oct 14 16:50 Integrating AI/ML into Biologics Discovery: Design, Optimization, Developability, and Immunogenicity How AI supports biologic drug discovery, from designing molecules to predicting how easily they are made and whether the body attacks them. Talk Thu Oct 15 12:20 Title TBA Therapeutic peptide and GLP engineering Talk Thu Oct 15 12:20 Title TBA Analytics & Screening